TG Therapeutics, Inc. (TGTX) Annual Report: Key Investor Insights and Potential Price Movers

Overview

TG Therapeutics, Inc. (“TGTX” or the “Company”) has filed its Annual Report on Form 10-K for the fiscal year ended December 31, 2025. This report contains several critical updates relevant for current and prospective shareholders. The Company, listed on Nasdaq Capital Market under the symbol TGTX, is a large accelerated filer and not a shell company. As of February 25, 2026, there were approximately 159.7 million common shares outstanding with a public float valued at \$2.5 billion as of June 30, 2024.

Key Financial and Strategic Highlights

• Completion of \$100 Million Share Repurchase Program:
  • The Company completed a \$100 million share repurchase program initiated in August 2024 and concluded in September 2025.
  • Repurchased a total of 3,502,334 shares at an average price of \$28.55 per share.
  • In September 2025, the Board authorized a new \$100 million share repurchase program, but no repurchases have occurred under this new authorization as of December 31, 2025.
• Commercialization Progress:
  • The Company is focused on the commercialization of BRIUMVI, its key product for B cell mediated diseases.
  • Key objectives include expanding the commercial infrastructure to drive BRIUMVI sales and maintaining a reliable supply chain to meet market demand.
• Financial Position:
  • TGTX has incurred substantial operating losses since inception, though management does not currently expect to raise additional capital. However, there is an acknowledgment that additional capital may be required depending on future circumstances.
  • The Company’s level of indebtedness and debt obligations could impact its ability to fund operations.
• Strategic Pipeline Development:
  • The Company is evaluating the potential of azer-cel, a new candidate for B-cell mediated diseases, including progressive forms of multiple sclerosis.
  • TGTX is committed to maintaining its “patient first” culture as it grows.

Risks and Uncertainties

The Company’s report details a comprehensive list of risk factors, several of which could be material to shareholders and influence share price:

• Commercialization Risks:
  • Inability to achieve broad market acceptance for BRIUMVI or other pipeline products could limit revenue generation.
  • Substantial competition may lead to reduced or eliminated commercial opportunities.
  • Exposure to unfavorable pricing regulations or reimbursement policies could harm the business.
  • Product liability lawsuits could result in significant liabilities and impact commercialization efforts.
• Regulatory and Development Risks:
  • Regulatory approval delays or failures would materially harm the business. Interim or preliminary positive clinical trial results may not translate into final approvals.
  • Company is subject to new legislation, regulatory proposals, and potential government agency disruptions, which could increase costs or delay product launches.
  • Expansion into new international markets brings additional compliance and operational risks.
• Dependence on Third Parties:
  • Reliance on third parties for clinical trials, manufacturing, and data generation; failures by these parties could delay or prohibit commercialization.
  • Intellectual property risks, including inability to enforce rights globally, potential infringement litigation, and possible need to license third-party IP on unfavorable terms.
• Operational and Governance Risks:
  • Future growth and business expansion may present operational challenges.
  • Certain executives, directors, and large shareholders have significant influence over shareholder votes and corporate actions.
  • Failures in IT systems or security breaches could disrupt product development or commercialization.
  • Economic conditions and regulatory changes (including tariffs) could affect business performance and financials.
• Stock and Market Risks:
  • Stock price is expected to remain volatile, potentially impacting investor returns.
  • Costs of public company compliance and management time commitment are significant.

Governance and Corporate Structure

• Board and Cybersecurity:
  • The Board receives regular updates regarding material cybersecurity threats and the effectiveness of information security processes.
  • Cybersecurity efforts are overseen by the Vice President of IT, who has over 25 years’ experience and multiple industry certifications.
• Audit and Compliance:
  • The annual audit was conducted by KPMG LLP, New York, NY, Firm ID 185.
  • The Company’s internal controls over financial reporting were attested to by the independent auditor as required by Section 404(b) of Sarbanes-Oxley.

Forward-Looking Statements

The report is replete with forward-looking statements regarding commercialization, financial projections, product development, regulatory approvals, and strategic initiatives. These statements are subject to risks and uncertainties, and actual results may differ materially from those projected.

What May Move the Share Price?

• Share Repurchase Programs: Completion of a major buyback and the initiation of a new \$100 million repurchase program could support share price and reflect management’s confidence in the business.
• Commercialization of BRIUMVI and Pipeline Progress: Success in expanding sales and achieving regulatory or market milestones for BRIUMVI, as well as progress with azer-cel or other pipeline assets, would likely be price sensitive.
• Regulatory or Legal Setbacks: Any material delay, denial, or major litigation loss could negatively impact the stock.
• Financial Surprises: Any deviation from projected cash needs, capital raising, or cost structure could affect valuation.
• Cybersecurity or Operational Events: IT failures, security breaches, or major disruptions could also impact valuation.

Conclusion

TG Therapeutics, Inc. enters 2026 with a strong cash position, ongoing share repurchase activity, and a focused strategy around BRIUMVI and pipeline development. However, the Company faces substantial competition, regulatory risk, and operational challenges. Investors should monitor the pace of BRIUMVI sales, progress of azer-cel, development of additional pipeline candidates, execution of the new share repurchase program, and any regulatory or legal developments.

Disclaimer: This summary is for informational purposes only and does not constitute investment advice or a recommendation to buy or sell any security. Forward-looking statements are subject to significant risks and uncertainties. Investors should review the full Annual Report and consult their financial advisor before making investment decisions.

View TG THERAPEUTICS, INC. Historical chart here